Association of sodium-glucose cotransporter 2 inhibitors with time to dementia: a population-based cohort study.

Cited by (138)

Items 101–138 of 138

1. Early-Onset Dementia Risk Escalates with Diabetes Duration: Insights from a Nationwide Cohort Study
   Ji‐Hong Park, Sun-Joon Moon, Da Yeon Lee, Ji-Hee Ko, Han Na Jang, Hyemi Kwon, Se‐Eun Park, Kyungdo Han, Eun‐Jung Rhee, Won‐Young Lee · 2025 · Endocrinology and Metabolism
2. Dapagliflozin restores odour‐induced functional integration of primary olfactory cortex circuit but not olfactory‐related regional brain activation in patients with type 2 diabetes: A 16‐week randomised comparative study
   Xin Li, Ying Zhang, Yan Bi, Jiaming Lu, Zhou Zhang, Cheng Ji, Bing Zhang, Qian Li, Shuang Wang, Jiu Chen et al. · 2025 · Diabetes Obesity and Metabolism
3. Baseline HbA1c and dementia risk at SGLT2i initiation in type 2 diabetes
   Jiaqiang Zhang, Yangyang Wang, Zhongyuan Lu, Yi Yang, Jiao Wang, Liang Zhao, Fangfang Li, Mengrong Miao, Wan‐Ming Chen, Szu‐Yuan Wu et al. · 2025 · Diabetes Obesity and Metabolism
4. Diabetes medications and dementia risk: Comparisons of SGLT2 inhibitors, GLP-1 RAs, metformin, and their combinations
   Gabrielle Nemeh, Aubrey L. Doede, Raphael E. Cuomo · 2025 · Diabetes Epidemiology and Management
5. A decade of SGLT2 inhibitors: Lessons learned and the road ahead in type 2 diabetes
   Tomohiko Kimura, Kohei Kaku · 2025 · Journal of Diabetes Investigation
6. Neuroprotective Potential of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in Type 2 Diabetes: A Narrative Review
   Rupanshu Rupanshu, Ajaybir S Buttar · 2025 · Cureus
7. Metabolic and immune dysfunction at the crossroads between type 1 diabetes and neurodegeneration
   Francesca D’Addio, Loredana G Bucciarelli, Maria Elena Lunati, Paolo Fiorina · 2025 · Metabolism
8. Measuring Sodium Transport in Cells with Nuclear Magnetic Resonance
   Juntao Xia, Yu Yin, Yun Chen, Xuetao Wu, H. F. Li, Y. Liu, Qingping He, Yun Ji, Ke Ma, Bona Dai et al. · 2026 · Journal of the American Chemical Society
9. Age at type 2 diabetes onset and risk of dementia: The modifying role of genetic susceptibility and mitochondrial function
   Wanqing Dong, Qibin Yuan, Benrui Wu, Shiteng Gao, Yingyu Zhang, Ying Pan, K. S. Zhou, Hongwei� Jiang · 2026 · The journal of nutrition health & aging
10. Repurposing SGLT2 and DPP‐4 inhibitors for mild cognitive impairment in type 2 diabetes mellitus: Insights from proteomics, target prediction and molecular docking
    Shams T Osman, Perihan A. Elzahhar, Md Abdul Hakim, Akeem Sanni, Noha Alaa Hamdy, Waziha Tasnim Purba, Md Mostofa Al Amin Bhuiyan, Sherifdeen Bamidele Onigbinde, Vishal Sandilya, Nayera W. Hassan et al. · 2026 · British Journal of Pharmacology
11. Oligodendrocyte Dysfunction in Alzheimer's Disease: Integrating Spatial Epigenomics and Metabolic Circuitry in Demyelination - A Critical Review.
    Lian Jian, Yu-Qing Liu, Wei-Jun Peng · 2026 · Ageing Research Reviews
12. Sodium-Glucose Cotransporter 2 Inhibitors and Dementia Risk in Patients With Psychiatric Disorders
    David T. Liebers, Tianshe He, Rebecca A. Betensky, Chunlei Zheng, Kaitlin N. Swinnerton, Jacobson Sean, Linden Huhmann, Mary T. Brophy, Nhan Do, Paola Gilsanz et al. · 2026 · JAMA Network Open
13. Apoptosis protein markers in comorbid type 2 diabetes mellitus and depression; relationships with cognitive performance, incident dementia, and white matter hyperintensities
    Sofia E. Perfetto, Myuri T. Ruthirakuhan, Yuen Yan Wong, Si Won Ryoo, Celine H.L. Huang, Fan Fan, Meghan J. Chenoweth, Sean M. Nestor, Ana C. Andreazza, Maged Goubran et al. · 2026 · Journal of Affective Disorders
14. use of SGLT2 inhibitors in the treatment of cognitive disorders
    Marta Lato, Konrad Iberszer, Maria Litwiniuk, Marcin Zaniuk, Kamil HURKAŁA, Dominika ANTONIK, Barbara Denys, Karolina Góra, Patryk Zimnicki, Wojciech Zdziennicki · 2023 · Journal of Education Health and Sport
15. Recent advances in perioperative care of patients using new antihyperglycaemic drugs and devices dedicated to diabetes
    Rami El Ojaimi, Gaëlle Cheisson, Emmanuel Cosson, Carole Ichaï, Sophie Jacqueminet, Bogdan Catargi, Alexandre Ouattara, Igor Tauveron, Paul Elie Valensi, Dan Benhamou · 2024 · Anaesthesia Critical Care & Pain Medicine
16. New advances in the treatment of Alzheimer's disease with antidiabetic drugs
    Jingfen Wang · 2023 · International Journal of Frontiers in Medicine
17. 13 C tracing in synaptosomes reveals that SGLT2 inhibition with dapagliflozin prevents metabolic deficits in the 5X-FAD model of Alzheimer’s Disease
    Marisa Mekkittikul, Cansheng Zhu, Bezawit T. Danna, Xiaohong Zuo, Amy Rios, Krista Yang, Miranda Villanueva, Devanshi Agarwal, Daniel Castro, Xuelin Gu et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
18. Diabetes and Alzheimer's Disease
    Zachary T. Bloomgarden · 2025 · Journal of Diabetes
19. Exploring SGLT2 Inhibitors’ Advantage Over Thiazolidinediones in Neurodegenerative Prevention: A Real-World Data Analysis (Preprint)
    Sang Joon Park, Hye Jeong Kim, Dong Won Byun, Kyoil Suh, Hyeon‐Jong Yang, Inho Lee, Soon Hyo Kwon, Min Jae Kim, Ji‐Oh Mok, Sung Wan Chun et al. · 2024
20. Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists for Dementia Risk: A Real-World Study
    Filippos Anagnostakis, Michail Kokkorakis, Shrihari Nagarajan, Georgia Anastasiou, Christos Socrates Mantzoros · 2024 · SSRN Electronic Journal
21. Dapagliflozin ameliorates intestinal stem cell aging by regulating the MAPK signaling pathway in Drosophila
    Jinhua Yan, Chenxi Feng, Hanmei Zhang, Ting Luo, Haiyang Chen, Haiou Chen · 2025 · Frontiers in Cell and Developmental Biology
22. Causal relationship and shared genetic pathways between diabetic kidney disease and cognitive impairment: a Mendelian randomization study
    Ke Yu, Yanqing Chi, Qian Wang, Yongzhe Chen, Ning Han, Ying Li · 2025 · Renal Failure
23. Measure Sodium Transport in Cells with NMR
    Juntao Xia, Yu Yin, Yun Chen, Xuetao Wu, Haoyu Li, Yaqin Liu, Qingping He, Yun Ji, Ke Ma, Bona Dai et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
24. Comparative Risk of Dementia after Initiation of SGLT2 Inhibitors vs. GLP-1 Receptor Agonists in T2D
    Fu‐Shun Yen, James Cheng-Chung Wei, Shih‐Yi Lin, Yu‐Hsin Yen, Yuhan Huang, Fuu‐Jen Tsai, Chii‐Min Hwu, Chih-Cheng Hsu · 2025 · SSRN Electronic Journal
25. Mechanistic role of gliflozins-induced ketosis in epileptogenesis and epilepsy: Rubric known and unknown
    Elyasa Mustafa Elfaki, Hayder Mutter Al-Kuraishy, Ali Ismail Al-Gareeb, Ali K. Albuhadily, Duaa Eliwa, Athanasios T. Alexiou, Marios Papadakis, Gaber El‐Saber Batiha · 2025 · Neuroscience
26. Insulin use in diabetes association with cognitive impairment and dementia incidence
    Sajjad Hajihosseini, Dorsa Moharerzadeh Kurd, Fatemeh Nouroozi, Shayesteh Haghighi, Naeemeh Dini, Yeganeh Ghobadi, Negin Tehrani, Mehregan Shahrokhi, Mohaddeseh Belbasi, Haleh Alizadeh et al. · 2025 · BMC Pharmacology and Toxicology
27. Cognitive impairment and type 2 diabetes mellitus: focus of sodium–glucose cotransporter 2 inhibitors treatment
    Pravachana Malakapogu, Zuha Shyma, Sahana Shetty, Debasis Bagchi, Sonal Sekhar Miraj · 2025 · Elsevier eBooks
28. Additional file 1 of Empagliflozin targets Mfn1 and Opa1 to attenuate microglia-mediated neuroinflammation in retinal ischemia and reperfusion injury
    Zhenlan Yang, Liu, Yidan, Chen, Xuhao, Huang, Shaofen, Li, Yangyang, Guitong Ye, Cao, Xu, Su, Wenru, Zhuo, Yehong · 2023 · Figshare
29. Mechanisms and Research Progress of SGLT-2 Inhibitors in Diabetes Mellitus-Related Cognitive Impairment
    Yutong Li, Murong Xu, Ying Tang, Xiaotong Zhao, Mingwei Chen · 2026 · Current Diabetes Reviews
30. The impact of antidiabetic drugs on dementia risk: a Bayesian network meta-analysis
    Yang Yu, Xu Peng, Chang Su, Yangguang Bai, Dan Hou · 2026 · Frontiers in Endocrinology
31. Benzbromarone as a Novel Candidate for Preventing Alzheimer's Disease: Evidence From Real‐World Data Screening and in Vitro Validation
    Sho Sakagami, Yuya Yoshida, Shota Uemura, Taisei Kumamoto, Ryotaro Tsukamoto, Takumi Nishi, Shimpei Kawano, Kohei Fukuoka, Hanami Ino, Kengo Hamamura et al. · 2026 · Clinical and Translational Science
32. Sotagliflozin improves cognitive deficits and attenuates neuroinflammation of Alzheimer's disease
    Yuye Ning, Meilin Chen, Hao Yang, Jianping Jia · 2026 · Neurotherapeutics
33. From diabetic foot to dementia: A neurovascular continuum linking systemic diabetic vasculopathy, cerebral small vessel disease, and glymphatic dysfunction
    Yuriko Inoue, Tatsunori Oguchi, Akio Inoue, Mikako Tanaka, Akiko Sasaki, Koji Saito, Hiromitsu EZURE, Naruhito Otsuka · 2026 · Biomedicine & Pharmacotherapy
34. Dementia in type 2 diabetes: risk factors, disease processes and opportunities for prevention across the lifespan
    Jan F. de Leijer, Geert Jan Biessels, Frank L.J. Visseren, Thomas T. van Sloten · 2026 · Diabetologia
35. Association between different sodium–glucose co-transporter 2 inhibitors and the risk of dementia: a network meta-analysis
    Zhongru Meng, Wu Hui, Yang Miao, Wang Qi, Mingzhu Sha · 2026 · Frontiers in Endocrinology
36. Glucose-Lowering Therapies and Cognitive Decline: From Molecular Mechanisms to Clinical Evidence and Future Perspectives
    Margherita Grasso, Viviana Maggio, Filippo Caraci, Manfredi Rizzo · 2026 · Advances in Therapy
37. Promoting Healthy Aging with Gerotherapeutic Medications
    Oh Sung Kwon, Iman M. Al‐Naggar · 2026 · Springer eBooks
38. Diabetes‐Associated Cognitive Impairment: Pathophysiology and Emerging Therapies
    Osman Corbali, Priyanka Menon, Halil Ibrahim Corbali, Ram Jagannathan, Allan I. Levey · 2026 · Annals of Clinical and Translational Neurology